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and KRAS mutations are important 
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non-small cell lung cancer. J Thorac Oncol 
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In Response:
We read with interest the letter 
from Compagnone et al.,1 entitled “KRAS 
mutation spectrum notably diverges from 
non–small-cell lung cancer to colorectal 
carcinomas.” The authors describe their 
institutional experience with KRAS test-
ing in colorectal cancer and non small 
cell lung cancer (NSCLC). In particular, 
they report that the distribution of KRAS 
mutations in NSCLC is different from 
that in colorectal cancer, with a higher 
proportion of c.37G . T and delins 
mutations of codon 15. These muta-
tions may not reliably be detected by 
commercial kits. The authors stress the 
importance of laboratory technique in 
selecting which molecular tests to imple-
ment in practice.
We agree with the authors that 
quality assurance for molecular test-
ing is a critical issue, but question 
the relevance of this in the context of 
KRAS mutation testing in NSCLC. The 
importance of KRAS testing in NSCLC 
is clearly different from that of KRAS 
testing in colorectal cancer, where data 
support KRAS as a predictive biomarker 
for epidermal growth factor recep-
tor (EGFR)-directed therapy. There is 
a need for consistent and reliable data 
demonstrating the predictive value of a 
biomarker before it is incorporated into 
routine clinical practice. The authors 
state that KRAS mutations are gener-
ally associated with lack of response 
to EGFR tyrosine kinase inhibitors. 
However, as stated both in our review2 
and that of Roberts et al.,3 the available 
data do not support the routine use of 
KRAS testing as a predictive biomarker 
for lung cancer.
The point is also made that KRAS 
mutation testing may be used to predict 
for the absence of an EGFR mutation or 
anaplastic lymphoma kinase transloca-
tion. This point was discussed at length 
when formulating our consensus recom-
mendations. Ultimately, it was felt there 
was not a strong rationale to perform 
KRAS testing to predict the results of 
EGFR testing. We believe the data bet-
ter support EGFR mutation testing in all 
patients with advanced NSCLC and non-
squamous histology. The findings from 
Compagnone et al., that nearly 15% of 
KRAS mutations might be missed dur-
ing commercial testing rather than direct 
sequencing, if anything, reinforces this 
point of view. Although KRAS testing 
might be helpful in a research setting to 
select patients for clinical trials of rast 
sarcoma (RAS)-directed therapy, there 
may be potential harm from a strategy 
that routinely employs KRAS testing. 
Given the conflicting information about 
the utility of RAS testing, there is poten-
tial for patients with KRAS mutations 
not to receive an EGFR tyrosine kinase 
inhibitor. However, available data from 
trials such as the Sequential Tarceva in 
Unresectable NSCLC trial of mainte-
nance erlotinib4 and the IRESSA Non-
Small Cell Lung Cancer Trial Evaluating 
Response and Survival against Taxotere 
trial5 comparing gefitinib versus doc-
etaxel showed similar survival outcomes 
for RAS mutated and wild-type patients.
In conclusion, we are of the opin-
ion that the findings of Campognone et 
al. are interesting, but do not change our 
recommendation against the routine use 
of RAS testing in patients with NSCLC.
Peter M. Ellis, MBBS, PhD
Juravinski Cancer Centre
Hamilton, ontario, Canada
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TABLE 1. KRAS Exon 2 Mutation Spectrum in Colorectal (CRC) and Non-small Cell Lung (NSCLC) Cancers
Mutationa c.34G>A c.34G>T c.34G>C c.35G>A c.35G>C c.35G>T c.37G>A c.37G>T c.38G>A Delinsb
CRC 32 57 9 218 39 129 1 4 133 11
 5 9 1.4 34.4 6.1 20.4 0.1 0.6 21 1.7
NSCLC 1 72 1 28 13 30 0 14 14 13
 0.5 38.7 0.5 15 7 16.1 0 7.5 7.5 7
aEnriched tumor zones were selected from fixed material on HE-stained sections and DNA was extracted from three pinches per sample using the DNA QIAamp® micro-kit 
(Qiagen). Exon 2 of the KRAS gene (NM_033360) was analyzed by sequencing after PCR amplification using primer pair 5AAGGCCTGCTGAAAATGACTG/5CAAAGAATGGTC
CTGCACCAG. Sequences were compared with the reference sequences using the SeqScape® software. The variants were encoded according to the Human Genome Variation Society 
recommendations (http://www.hgvs.org/mutnomen).
bDelins mutations involving codons 12 and 13 in CRC are c.34_35delinsAT (2), c.34_35delinsTT (4), c.34_35delinsCT (1), c.34_35delinsTA (2), c.38_39delinsTT (1), and 
c.38_39delinsAT (1) and in NSCLC are c.34_35delinsTT (5), c.38_39delinsTT (1), c.34_35delinsAT (1), c.34_35delinsAA (1), c.34_35delinsTA (1), c.37_38delinsTA (1), 
c.34_35delinsTC (1), c.33_34delinsCT (1), and c.36_37delinsGT.
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